Colorectal Cancer Survivors' Receptivity toward Genomic Testing and Targeted Use of Non-Steroidal Anti-Inflammatory Drugs to Prevent Cancer Recurrence.
Journal
Journal of community genetics
ISSN: 1868-310X
Titre abrégé: J Community Genet
Pays: Germany
ID NLM: 101551501
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
11
02
2021
accepted:
22
12
2021
pubmed:
9
1
2022
medline:
9
1
2022
entrez:
8
1
2022
Statut:
ppublish
Résumé
Genomic testing and targeted use of non-steroidal anti-inflammatory drugs (NSAIDs) may mitigate cancer recurrence risks. This study examines colorectal cancer (CRC) survivors' interest and receptivity to these strategies. Patients diagnosed with stage I-III CRC in 2004-2012 were recruited through the New Mexico Cancer Registry to complete a cancer survivorship experiences survey. We assessed interest in genomic testing, daily aspirin (ASA) and NSAID use, and receptivity to future daily ASA/NSAIDs. Descriptive statistics and multivariable logistic regression models estimated factors associated with genomic testing interest. Receptivity to future ASA/NSAIDs use was estimated for non-users of ASA/NSAIDs. Among CRC survivors (n = 273), 83% endorsed interest in genomic testing, 25% were ASA users and 47% ASA/NSAIDs users. In our final model, genomic testing interest was associated with being uncoupled [OR = 4.11; 95% CI = 1.49-11.35], low income [OR = 0.35, 95% CI: 0.14-0.88], smoking history [OR = 0.35, 95% CI: 0.14-0.90], low [OR: 0.33, 95% CI: 0.07-1.43] and moderate [OR: 0.26, 95% CI: 0.11-0.61] health literacy, and personal CRC risk worry [OR: 2.86, 95% CI: 1.63-5.02, p = 0.0002]. In our final model, ASA use was associated with age [OR: 1.05, 95% CI: 1.01-1.10] and cardiovascular disease history [OR: 2.42, 95% CI: 1.23-4.73, p = 0.010]. Among non-users ASA/NSAIDs, 83% reported receptivity to ASA/NSAIDs to reduce cancer risks, and no significant correlates were identified. The majority of survivors' expressed genomic testing interest and endorsed receptivity toward ASA/NSAIDs use for cancer risk management. Further research to optimize ASA/NSAIDs use guided by genomic testing is warranted.
Identifiants
pubmed: 34997901
doi: 10.1007/s12687-021-00574-9
pii: 10.1007/s12687-021-00574-9
pmc: PMC8941057
doi:
Types de publication
Journal Article
Langues
eng
Pagination
201-214Subventions
Organisme : NCI NIH HHS
ID : K07 CA215937
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA256043
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA256043
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Cancer Manag Res. 2018 Oct 15;10:4631-4640
pubmed: 30410398
J Genet Couns. 2013 Feb;22(1):138-51
pubmed: 22911325
J Natl Compr Canc Netw. 2009 Sep;7(8):778-831
pubmed: 19755046
CA Cancer J Clin. 2018 Nov;68(6):425-445
pubmed: 30285281
N Engl J Med. 2018 Oct 18;379(16):1529-1539
pubmed: 30146931
Br J Cancer. 2015 Jul 28;113(3):403-10
pubmed: 26180924
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1911-1918.e2
pubmed: 30130624
Eur Heart J. 2012 Jul;33(13):1635-701
pubmed: 22555213
Dig Dis Sci. 2006 Dec;51(12):2348-52
pubmed: 17078001
Cancer Res. 1998 Nov 15;58(22):5248-57
pubmed: 9823339
N Engl J Med. 2018 Oct 18;379(16):1509-1518
pubmed: 30221597
Gastroenterology. 2009 Nov;137(5):1621-7
pubmed: 19622357
Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):461-72
pubmed: 22122763
Public Health Genomics. 2014;17(1):48-60
pubmed: 24435063
Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1275-1282
pubmed: 29593011
Psychooncology. 2016 Dec;25(12):1434-1440
pubmed: 26863926
Am J Clin Oncol. 2006 Apr;29(2):123-6
pubmed: 16601428
Lancet. 2019 May 25;393(10186):2155-2167
pubmed: 31226053
Am J Public Health. 2005 Jul;95(7):1149-55
pubmed: 15983270
J Cancer Surviv. 2019 Jun;13(3):459-467
pubmed: 31111302
Pharmacoepidemiol Drug Saf. 2010 Aug;19(8):834-42
pubmed: 20681002
Trials. 2011 Dec 14;12:261
pubmed: 22168568
CA Cancer J Clin. 2015 Nov-Dec;65(6):428-55
pubmed: 26348643
Cancer Prev Res (Phila). 2017 Mar;10(3):208-218
pubmed: 28154202
Support Care Cancer. 2021 Dec;29(12):7289-7297
pubmed: 34036439
Genet Med. 2009 Jan;11(1):42-65
pubmed: 19125127
Gastroenterology. 2008 Jan;134(1):29-38
pubmed: 18022173
Breast Cancer Res Treat. 2016 Apr;156(3):549-555
pubmed: 27059031
Fam Med. 2004 Sep;36(8):588-94
pubmed: 15343421
Genet Med. 2009 Jan;11(1):35-41
pubmed: 19125126
J Natl Compr Canc Netw. 2013 Feb 1;11(2):190-209
pubmed: 23411386
Am J Prev Med. 2006 Jan;30(1):74-7
pubmed: 16414427
Eur Heart J. 2019 Sep 7;40(34):2922-2923
pubmed: 31005987
Psychooncology. 2004 Jun;13(6):367-76
pubmed: 15188444
J Natl Cancer Inst. 2004 Feb 18;96(4):261-8
pubmed: 14970275
JNCI Cancer Spectr. 2020 Jun 19;4(5):pkaa054
pubmed: 33225206
Pharmacogenet Genomics. 2014 Jul;24(7):348-55
pubmed: 24911662
Cancer Res. 2020 Jun 1;80(11):2114-2124
pubmed: 32269045
Diabetes Care. 2001 Jun;24(6):1069-78
pubmed: 11375373
Lancet. 2010 Nov 20;376(9754):1741-50
pubmed: 20970847
Colorectal Dis. 2015 May;17(5):O108-14
pubmed: 25704636
Eur J Epidemiol. 2011 Nov;26(11):863-76
pubmed: 21938478
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Chest. 2012 Feb;141(2 Suppl):e637S-e668S
pubmed: 22315274
J Gen Intern Med. 2008 May;23(5):561-6
pubmed: 18335281
J Gastrointest Cancer. 2019 Jun;50(2):221-229
pubmed: 29335847
Ann Intern Med. 2016 Jun 21;164(12):836-45
pubmed: 27064677
Gut. 2012 Feb;61(2):255-61
pubmed: 21890814
N Engl J Med. 2003 Mar 6;348(10):883-90
pubmed: 12621132
Curr Oncol. 2016 Dec;23(6):e546-e555
pubmed: 28050143
Lancet. 2012 Apr 28;379(9826):1591-601
pubmed: 22440947
Cancer Sci. 2019 Oct;110(10):3018-3026
pubmed: 31361372
Stroke. 2011 Feb;42(2):517-84
pubmed: 21127304
J Clin Oncol. 2017 Aug 20;35(24):2806-2813
pubmed: 28617623
Gut. 2014 Nov;63(11):1755-9
pubmed: 24488498
Ann Surg Oncol. 2020 Aug;27(8):2740-2749
pubmed: 32080809
J Cancer Surviv. 2013 Sep;7(3):300-22
pubmed: 23475398
Am J Prev Med. 2014 May;46(5):440-8
pubmed: 24745633
J Cancer Surviv. 2013 Jun;7(2):253-61
pubmed: 23417882
Medicine (Baltimore). 2016 Feb;95(6):e2723
pubmed: 26871811
J Cancer Surviv. 2017 Apr;11(2):233-245
pubmed: 27837443
Health Expect. 2018 Dec;21(6):1150-1158
pubmed: 30085384
Cancer. 2015 Sep 15;121(18):3281-9
pubmed: 26036338
Support Care Cancer. 2016 Feb;24(2):555-562
pubmed: 26108170
Ethn Dis. 2005 Autumn;15(4):620-6
pubmed: 16259485
J Oncol Pract. 2016 Dec;12(12):e964-e973
pubmed: 27221992
Cancer Prev Res (Phila). 2012 Feb;5(2):164-78
pubmed: 22084361
Genet Med. 2013 Dec;15(12):933-40
pubmed: 23639899
Nature. 2015 Oct 15;526(7573):343-50
pubmed: 26469045
Cancer Treat Rev. 2018 Mar;64:30-39
pubmed: 29459248
Int J Mol Sci. 2020 Nov 27;21(23):
pubmed: 33260951
Cancer Causes Control. 2019 Dec;30(12):1327-1339
pubmed: 31655944
Am J Cardiol. 2011 Jan;107(1):41-6
pubmed: 21146684
Nicotine Tob Res. 2016 Dec;18(12):2273-2277
pubmed: 27613923
Cancer Epidemiol Biomarkers Prev. 1999 Jul;8(7):635-9
pubmed: 10428202
J Natl Cancer Inst. 1997 Dec 3;89(23):1758-62
pubmed: 9392616
N Engl J Med. 2012 Oct 25;367(17):1596-606
pubmed: 23094721
JAMA. 2009 Aug 12;302(6):649-58
pubmed: 19671906
JAMA. 2016 Jun 21;315(23):2564-2575
pubmed: 27304597
Lancet. 2018 Sep 22;392(10152):1036-1046
pubmed: 30158069
Lancet Oncol. 2016 Apr;17(4):407-409
pubmed: 26947330
J Community Health. 2020 Aug;45(4):820-827
pubmed: 32112236
Psychooncology. 2020 Apr;29(4):632-638
pubmed: 32026561
Am J Prev Med. 2018 Dec;55(6):830-838
pubmed: 30352719
Ann Intern Med. 2009 Mar 17;150(6):396-404
pubmed: 19293072
Eur Heart J. 2019 Feb 14;40(7):607-617
pubmed: 30561620
N Engl J Med. 2003 Mar 6;348(10):891-9
pubmed: 12621133
Cancer Causes Control. 2014 Jan;25(1):99-110
pubmed: 24158780
J Oncol Pract. 2017 Jul;13(7):e590-e601
pubmed: 28628391
Am Psychol. 2015 Feb-Mar;70(2):91-104
pubmed: 25730717
Dis Colon Rectum. 2013 Nov;56(11):1304-19
pubmed: 24105007